At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Mar 2, 2026 at 07:00 ET
Royalty Pharma announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Sun will lead the company's royalty business in Asia from Hong Kong, signaling a strategic expansion into the region's growing biotech innovation market.
- Kenneth Sun appointed as Senior Vice President and Head of Asia, effective May 2026
- Sun will be based in Hong Kong and lead Royalty Pharma’s royalty business in Asia
- Sun previously served as Head of Asia Pacific Healthcare Investment Banking at Morgan Stanley
- Asia-based biotech innovation is accelerating, with $130 billion in Chinese medicine out-licensing deals announced in 2025, up from $14 billion in 2021
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access